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Hyperkalemia in patients infected with the human immunode- Several electrolyte disturbances have been described
ficiency virus: Involvement of a systemic mechanism. in individuals infected with the human immunodeficiency
Background. The appearance of hyperkalemia has been de- virus (HIV) [1, 2]. Among them, a number of casesscribed in human immunodeficiency virus (HIV)-positive pa-
of hyperkalemia have been reported in HIV-positivetients treated with drugs with amiloride-like properties. Recent
subjects treated with pentamidine [3, 4] or trimethoprim-in vitro data suggest that individuals infected with HIV have
alterations in transcellular K1 transport. sulfamethoxazole [5, 6], or having hyporeninemic hypo-
Methods. With the objective of examining the presence of aldosteronism [1, 7, 8]. In these three circumstances, an
alterations in transmembrane K1 equilibrium in HIV-positive impaired renal excretion of potassium has been impliedpatients, we designed a prospective, interventional study in-
as the cause of the increase in plasma potassium; thisvolving 10 HIV-positive individuals and 10 healthy controls,
hyperkalemia was characterized by a delayed, progres-all with normal renal function. An infusion of l-arginine (6%,
intravenously, in four 30-min periods at 50, 100, 200, and 300 sive onset. Further data, however, have raised the possi-
ml/hr) was administered, and plasma and urine electrolytes, bility that HIV infection might be accompanied by alter-
creatinine, pH and osmolality, total and fractional sodium and ations in the ionic transport mechanisms involvingpotassium excretion, transtubular potassium gradient, plasma
transmembrane potassium equilibrium. In this regard,insulin, renin, aldosterone, and cortisol were measured.
an alteration in K1 channels has been proposed as aResults. A primary disturbance consisting of a significant
rise in plasma [K1] induced by l-arginine was detected in only major pathogenetic mechanism in AIDS-related demen-
the HIV patients but not in the controls (P , 0.001 between tia [9]. Furthermore, even though pentamidine and tri-
groups). A K1 redistribution origin of the hyperkalemia was
methroprim-sulfamethoxazole appeared to act by thesupported by its rapid development (within 60 min) and the
blockade of an amiloride-sensitive site in the distal seg-lack of significant differences between HIV-positive individuals
and controls in the amount of K1 excreted in the urine. The fact ments of the nephron, no convincing explanation has
that the HIV-positive individuals had an inhibited aldosterone been provided to date about the increased frequency
response to the increase in plasma K1 suggested a putative of hyperkalemia related to these drugs in HIV-infected
mechanism for the deranged K1 response.
individuals. This phenomenon raises the possibility thatConclusions. These results reveal that HIV-infected individ-
HIV patients may have a defect in systemic K1 equilib-uals have a significant abnormality in systemic K1 equilibrium.
This abnormality, which leads to the development of hyperka- rium. To give more support to the probability of an
lemia after the l-arginine challenge, may be related, in part, alteration in systemic K1 equilibrium, in a case reported
to a failure in the aldosterone response to hyperkalemia. These by Lachaal and Venuto [3], the increase in plasma K1results provide a new basis for understanding the pathogenesis
started during the first day of pentamidine administra-of hyperkalemia in HIV individuals, and demonstrate that the
tion, several days before the appearance of renal insuffi-risk of HIV-associated hyperkalemia exists even in the absence
of amiloride-mimicking drugs or overt hyporeninemic hypoal- ciency, and too early to be considered as secondary to
dosteronism. an amiloride-like tubular effect. Based on these data, we
hypothesized that HIV infection might induce alter-
ations leading to deranged transmembrane turnover ofKey words: HIV, AIDS, aldosterone, potassium turnover, hyporenin-
emic hypoaldosteronism, amiloride. K1, which will augment plasma K1 independently of any
putative renal effect. The aim of this study was, therefore,Received for publication October 8, 1998
to examine the presence of a systemic alteration in K1and in revised form February 5, 1999
Accepted for publication February 19, 1999 equilibrium in patients infected with HIV. With this pur-
pose, we used an infusion of the cationic aminoacid 1999 by the International Society of Nephrology
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l-arginine as a research tool to increase plasma K1 by K1 tween 9:30 and 10:00 a.m. After the insertion of a butter-
fly needle in a peripheral arm vein, the subjects were inredistribution between the intracellular and extracellular
compartments. at least 30 minutes of rest following an overnight fast.
All were submitted to a moderate water load (10 ml/kg
body wt) to ensure the availability of an adequate volume
METHODS of diuresis during the procedure. The infusion was de-
Selection and characteristics of the subjects signed according to previous studies [15, 16], using a dose
of l-arginine adequate to induce renal hemodynamicThe study was carried out on 10 HIV patients (9 males
changes but without evidence of hyperkalemia in no-and 1 female) aged 35.7 6 2.2 years (range 27 to 45
HIV people. The subjects received a mean intravenousyears) and 10 controls (3 female and 7 male) who were
dose of 19.0 6 3.4 g (0.29 6 0.02 and 0.28 6 0019 g/kghealthy volunteers, aged 41.0 6 4.2 years (range 20 to
body wt in HIV and control individuals, respectively)56 years). The putative causes of HIV infection were
of a 6% solution of arginine hydrochloride (Veyron ethomosexual (N 5 5) or heterosexual (N 5 2) sexual
Froment, Marseilles, France) in two hours. The velocitycontact and parenteral drug addiction (N 5 3). Eight
of the infusion was 50, 100, 200, and 300 ml/hr in eachpatients were included in group IV of the Centers for
one of four 30-minute periods. Blood and urine samplesDisease Control (CDC) classification system, and two
were withdrawn at baseline and at 60 and 120 minutes;patients were in CDC group II. In the HIV-positive
a further blood sample was extracted 60 minutes afterindividuals, CD4 were more than 500 in one patient,
the end of the l-arginine infusion. Arterial blood pres-between 200 and 500 in three, between 100 and 200 in
three, and less than 100 in three cases. Body weight was sure was regularly monitored during the procedure.
66.4 6 4.6 kg (range 45 to 80 kg) in HIV patients and
Analytical methods69.3 6 4.8 kg (range 50 to 84 kg) in controls. Four patients
were on trimethoprim-sulfamethoxazole at the time of K1, Na1, Cl2, osmolality, and creatinine concentra-
the study. Four patients were taking combination ther- tions in plasma and urine were measured with usual
apy with nucleoside analogues and protease inhibitors. routine methods. Creatinine clearance (CCr), total and
At the time of the study, no patient was receiving drugs fractional sodium excretion (FENa), total and fractional
with potential effects on K1 metabolism other than tri- potassium excretion (FEK), and transtubular K1 gradient
methoprim-sulfamethoxazole; this exclusion involved (TTGK), were calculated. Plasma cortisol was measured
pentamidine, angiotensin-converting enzyme inhibitors, by a chemoluminescence method (Inmulite, DIPESA,
b blockers, prostaglandin inhibitors, distal diuretics, or Madrid, Spain). Radioimmunoassays were used for mea-
heparin [10]. suring plasma insulin (Linco Research Inc., St. Charles,
The purpose, nature, and potential risks of the study MO, USA), plasma renin activity (Sorin, Vercelli, Italy),
were explained to all of the subjects, and written in- and plasma aldosterone (Sorin).
formed consent was obtained before their participation.
StatisticsThe protocol was approved by our Institutional Review
Board and by the Review Comitee of the Fondo de The Gaussian distribution of the data was tested by
Investigaciones Sanitarias from the Ministerio de San- the Kolmogoroff–Smirnov test. Comparisons between
idad. two sets of data were done by Student’s t-test for un-
paired observations. Comparisons between data before
L-Arginine infusion procedure and after the l-arginine infusion were done by Student’s
The rationale for the use of l-arginine was based on t-test for paired observations. Regression analysis was
several previous studies that described the ability of this used to compare two continuous numerical variables,
cationic amino acid to induce an increase in plasma K1 and the chi-square method was applied for significance
[11–14]. The l-arginine infusion was chosen as the prefer- in 2 3 2 table distributions. All of the data are expressed
ential research maneuver instead of K1 infusions be- as mean 6 sd. A P value of less than 0.05 was considered
cause of the previously proven absence of risk and sec- significant.
ondary effects [15], the simplicity of administration, and
the similarity with frequently used treatments, as paren-
RESULTSteral nutrition or dietary supplements [15, 16]. The alter-
native procedure, namely, infusion of K1, was not used At baseline, three differences between the HIV-posi-
tive patients and the normal controls were evident: thebecause of its potential risks and the need of cannulation
of major veins. All of the studies were performed in the HIV-positive individuals had decreased plasma [Na1]
and plasma [HCO32] and increased plasma [Cl2] (TableClinical Research Facility of the Nephrology Service or
the Infectious Diseases ward. The tests were started be- 1). As a result of these combined data, baseline values
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Table 1. Plasma biochemical data in HIV patients and healthy controls at baseline and at the end of the l-arginine infusion
Plasma Na1 Plasma K1 Plasma Cl2
Plasma Cr Anion Bicarbonate
mEq/liter pH mg/dl gap mmol/liter Osmolality
Baseline
Patients 13561.2 4.260.5 10560.7 7.3660.01 0.9 60.1 8.6 63 21.260.6 283.0612.4
Controls 13961.6a 4.460.2 100.661.5a 7.3560.01 0.7 60.04 14.866.4a 23.860.6a 285.3618.2
End
Patients 13461.3 5.160.8b 10860.8 7.3560.02 1.1 60.4 5.7 64.1 20.860.7 284.3614.2
Controls 14060.7a 4.260.3a 10461.8a 7.3460.03 0.7 60.1 13.764.3a 22.460.4 286.1615
a P , 0.05 with respect to the other group
b P , 0.05 with respect to the baseline
c The anion gap was calculated as Na1-Cl2-HCO32
Table 2. Effects of l-arginine infusion on creatinine clearance and in the response to l-arginine infusion observed between
fractional excretion of sodium in HIV patients and controls
the HIV-positive and -negative individuals were not re-
Patients Controls lated to the differences in the urinary excretion of K1,
CCr FENa CCr FENa because both controls and HIV-positive individuals did
Time ml/min % ml/min % not have significant differences in the increase in K1
0 min 109 611.9 0.7 60.1 122610.8 0.7 60.1 filtration load, but also had a similar and rather constant
60 min 174 618.3a 160.2a 180624.2a 160.2a
fractional excretion of K1 (Table 3). In addition, no120 min 146 626.2 1.4 60.3a 127.5610 1.2 60.2a
differences in baseline K1 excretion were evident be-Abbreviations are: CCr, creatinine clearance; FENa, fractional excretion of
sodium. tween both groups. A trend to present a smaller TTGK
a P , 0.05 with respect to time zero
was evident in the HIV-positive group during the l-argi-
nine infusion, and the differences in TTGK reached sta-
tistical significance at the 60-minute time period (Table
3). When the data within the HIV-positive group wereof plasma anion gap were smaller in the HIV group.
analyzed as a function of the administration or withhold-Plasma albumin concentrations were also decreased in
ing of trimethroprim-sulfamethoxazole, no differencesthe HIV-positive individuals (plasma albumin HIV posi-
in K1 handling related to this treatment were detectedtive, 2.9 6 0.6; controls, 4.1 6 0.3, P , 0.01). These
(plasma K1 at baseline, 1 hr, and 2 hr for patients takingdifferences persisted throughout the l-arginine infusion
trimethroprim-sulfamethoxazole was 4.3 6 0.2, 4.7 6at a similar level (Table 1). The changes in plasma osmol-
0.08, 5.1 6 0.3 mmol/liter, respectively; for patients notality during l-arginine infusion did not reach statistical
taking trimethroprim-sulfamethoxazoleit was 4.4 6 0.2,significance (Table 1). All of the patients and controls,
4.8 6 0.4, 5.3 6 0.4 mmol/liter, respectively, P 5 NSexcept one, had normal K1 concentrations; there was
between groups; total urinary K1 at baseline at 1 hr, andonly one exception in the HIV group, in which one indi-
2 hr in patients taking trimethroprim-sulfamethoxazolevidual (patient 7) had decreased baseline K1 levels as a
was 2.6 6 1.5, 4.5 6 2.8, and 4.6 6 1.3 mmol/hr, respec-consequence of severe diarrhea lasting until two days
tively; for patients taking no trimethroprim-sulfamethox-before the study. In this patient, plasma K1 did not
azole it was 2.9 6 0.5, 6.28 6 0.7, 4.5 6 1.5 mmol/hr,increase with the l-arginine infusion (discussed later in
respectively, P 5 NS between groups). The doses ofthis article). In addition, a significant increase in CCr and
trimethroprim-sulfamethoxazole were, however, on asodium excretion (fractional and total) was observed
minimal, preventive range and probably were not highwith the l-arginine infusion. These data are shown in
enough to provoke any relevant action on renal potas-Table 2.
sium excretion. As a reference, the total K1 excretionAs a principal finding, our study revealed that the
in the controls at baseline, one hour, and two hours wasinfusion of l-arginine induced a significant rise in plasma
3.9 6 0.5, 4.4 6 0.3, 3.4 6 0.3 mmol/hr (P 5 NS with[K1] in only the HIV-positive patients (Fig. 1A). No
respect to the HIV individuals).changes in plasma [K1] were observed with the same
The effects of l-arginine on plasma insulin, plasmainfusion in the control individuals (P , 0.001 between
renin activity, and plasma aldosterone are representedgroups; Fig. 1B). The changes in [K1] occurred rapidly
in Table 4. No differences between both groups in theseand were significant from the first hour of the l-arginine
infusion (Fig. 1A). Potassium concentration returned to three variables were present at baseline (Table 4). As
expected, during the l-arginine infusion, a tendency tonormality within 60 minutes after the end of the infusion
(data not shown). As shown in Table 3, the differences increase the insulin levels was evident, albeit without
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Fig. 1. (A) Values of plasma K1 (mmol/liter)
in HIV patients before and during L-arginine
infusion. Mean values at zero, one, and two
hours (end) of l-arginine infusion. The aster-
isk indicates significant values of P. Patient 7,
who had hypokalemic values, has been omit-
ted from this figure (discussed in text). (B)
Values of plasma K1 (mmol/liter) in control,
healthy individuals before and during l-argi-
nine infusion. Mean values at zero, one, and
two hours (end) of l-arginine infusion.
reaching statistical significance. A small decrease oc- increased markedly in the controls after l-arginine,
curred in renin levels, which was near statistical signifi- whereas it persisted identically in the HIV patients (Ta-
cance at the P 5 0.059 level in the controls, but reached ble 5). Both ratios indicate the absence of an appropriate
a P value of 0.004 in the HIV-positive individuals. In aldosterone response to hyperkalemia in the HIV indi-
the control subjects, the plasma aldosterone concentra- viduals. Values of baseline plasma renin activity and
tion did not parallel, however, the decrease in plasma aldosterone within the range of hyporeninemic hypoal-
renin activity. Actually, a tendency to increase in plasma dosteronism were present in only HIV-positive patient
aldosterone was observed in these individuals (P 5 0.06). 7 (plasma renin activity, 0.4 ng/ml/hr; plasma aldoste-
On the contrary, the opposite tendency, that is, a de- rone, 1.8 ng/dl), who, however, was the only one with
crease in plasma aldosterone, was observed in the HIV- decreased plasma K1. Plasma cortisol values were nor-
positive group (P 5 0.08). Of note, this occurred in spite mal in all of the individuals (controls, 16.4 6 2.2 mg/dl;
of the putative stimulus represented by the increase in HIV positive, 15 6 1.9 mg/dl; P 5 NS between groups).
serum K1. Two further calculations were useful to evi- The infusion of l-arginine did not induce any significant
dence the discrepancies in the renin-aldosterone axis change in arterial pressure (data not shown) and also did
response to l-arginine infusion between the HIV-posi- not provoke any other reaction that could be detected by
tive individuals and controls. First, the ratio between clinical means.
plasma aldosterone and plasma K1, which was similar
between groups at baseline, became significantly higher
DISCUSSIONin the control group after the infusion of l-arginine,
These results disclose that HIV-infected individualswhereas it did not change and even tended to decrease
have a systemic abnormality in K1 equilibrium, whichin the HIV group (Table 5). In the same line of evidence,
the ratio between plasma renin and plasma aldosterone favors the development of hyperkalemia by a mechanism
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Fig. 1. Continued.
Table 3. Parameters of renal potassium management in HIV patients and controls
Patients Controls
K1 filtered loadc FEK1e K1 filtered loadc FEK1e
Time mmol/min TTKGd % mmol/min TTKGd %
0 min 0.460.06 5.7 62.4 11.362.5 0.560.05 6.7 61.2 14.461.4
60 min 0.860.1 3.9 62b 13.163.9 0.760.09 5.8 61.6 11.460.5
120 min 0.760.2 3.5 61.5a 11.562.1 0.560.04 4.1 61.1a 11.461.07a
a P , 0.05 with respect to the baseline
b P , 0.05 between groups
c K1 filtered load was calculated as plasma K1 concentration (mmol/liter) 3 CCr (ml/min)
d TTKG: transtubular potassium gradient, calculated as [K1]u 3 [Osm]p/[K1]p 3 [Osm]u
e FEK1, fractional excretion of K1
unrelated to renal K1 excretion. Accordingly, a systemic these mechanisms, however, can explain our current
findings. In the first place, no significant differences ex-disturbance affecting K1 redistribution was revealed un-
der challenge with l-arginine. isted between the HIV individuals and the controls in
the urinary management of K1, although the values ofThese data may significantly change the previous ideas
regarding the HIV-associated potassium disturbances. In TTKG suggest that a disturbed K1 secretion was present
in the HIV individuals (discussed later in this article).prior years, hyperkalemic episodes have been reported in
HIV patients that were attributed to factors involving Second, the similarities in plasma osmolality ruled out
that the differences in K1 are due to an osmotic effect.renal excretion of K1, that is, hyporeninemic hypoaldo-
steronism [3–7, 17], administration of pentamidine or Third, in spite of the reduced mean plasma albumin, the
similarities in baseline plasma and urinary K1 do nottrimethoprim-sulfamethoxazole [3, 5, 6, 18]. None of
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Table 4. Renin, aldosterone and insulin values in HIV patients and controls
Patients Controls
Reninb Aldosterone Insulin Reninb Aldosterone Insulin
Time ng/ml/hr ng/dl u/liter ng/ml/hr ng/dl U/liter
0 min 1.561.3 10.767.0 13.1 65.9 1.360.9 10.365.2 12.4 63.8
120 min 0.961.4a 9.468.4 18.6614.7 0.660.5 18.8611.2 17.6 615.6
a P , 0.05 with respect to the basal
b Renin denotes plasma renin activity
Table 5. Relationship between plasma aldosterone and plasma tion for the increased frequency of hyperkalemia in HIV
renin activity, and plasma aldosterone and plasma potassium
patients taking drugs with amiloride-like properties. The
Patients Controls relevant role of aldosterone in the acute response to a
Time PA/PRA PA/K1 PA/PRA PA/K1 potassium load was substantiated in earlier studies in
non-HIV populations [20, 21]. Other studies are, how-0 min 8.166 2.5 61.7 7.965.5 2.4 61.2
120 min 10.567 1.7 61.4 30.369.4a 4.662.6a ever, critical with this role of the absence of aldosterone
Abbreviations are: PA/PRA, relationship between plasma aldosterone and [22]. In addition to the possible role of aldosterone-
plasma renin activity; PA/K1, relationship between plasma aldosterone and
related mechanisms, other possible interpretations forplasma potassium.
a P , 0.05 between patients and controls the deranged K1 turnover in the HIV patients can be
raised. In this regard, in spite of the similar body weight
of controls and HIV individuals, the possibility that the
latter had a decreased skeletal muscle mass could befavor the existence of a decreased K1 intake in the HIV
taken into account. Such a reduced muscular mass maygroup, which might induce a different K1 equilibrium
decrease the space for potassium reuptake under theand adaptation. Fourth, the timing of the plasma K1
influence of insulin. This type of re-uptake is critical inincrease, that is, within the first hour of l-arginine infu-
the return to normality after hyperkalemia. Similarly,sion, diminishes the possible importance of a renal effect,
the existence in HIV patients of a lower extracellularwhich would require a longer time to become relevant.
volume in which to distribute the K1 driven from cellsIn fact, the time profile of the increased K1 could only
by l-arginine can be a factor influencing the altered K1be traced to K1 redistribution from the intracellular to
turnover. As an additional consideration, even thoughthe extracellular space. Fifth, even though no baseline
we believe that a renal defect in HIV patients cannotdata of the presence of hyporeninemic hypoaldosteron-
explain these findings by itself, it is possibile that a pre-ism were evident, with the exception of one patient,
viously existent, deranged renal K1 excretion could beour results support the possibility that the aldosterone-
partially involved in delaying the return of plasma K1releasing response to K1 was abnormal in the HIV-posi-
to normality. The main difficulty in accurately assessingtive individuals. Actually, these patients may have a
this issue is that a study would be required in a controlsubclinical form of aldosterone hyporesponsiveness,
group with an equivalent degree of hyperkalemia inresulting in an abnormal aldosterone response to the
which renal K1 excretion could be monitored. The exper-increase in plasma K1. The possible existence of a de-
imental approach to this topic, however, may involveranged aldosterone response in HIV has been suggested
substantial health risks to the volunteers.previously [17], but our current study provides the first
Our study reports the possibility of using l-argininedirect evidence of the existence of this type of alteration,
infusions as a research tool for the clinical examinationto our knowledge, in a group of patients without baseline
of K1 turnover. Even though this application has notabnormalities of plasma or urinary K1. The deranged
been specifically described in the past, its rationale isaldosterone response during the l-arginine infusion in
firmly supported on the previous data from the literaturethe HIV patients occurred without previous evidence of
[11–14].hyporeninism and, therefore, does not fit in the classic
The absence of increase in plasma K1 by l-arginineclinical picture of hyporeninemic hypoaldosteronism
in the control individuals differs from the hyperkalemia[19]. Experiments aimed to induce renin and aldosterone
reported by other authors [13, 14]. This outcome was,stimulation separately, that is, captopril test and low-
however, rather predictable, because we used a markedlydose angiotensin II infusions, may clarify the specific
smaller total dose over a longer time of administration.mechanisms involved. The data on TTKG are further
The groups reporting hyperkalemia in normal individu-suggestive of a decreased aldosterone effect in these
patients. Such a defect would provide a putative explana- als used l-arginine doses of approximately 0.5 g/kg body
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